Acumen Pharmaceuticals Inc (ABOS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...

By Yahoo! Finance | Nov 13, 2024 at 02:11 AM EST

The company aims to maintain study integrity by not conducting interim reviews for ALTITUDE AD. They plan to release data at the study end and cannot disclose ARIA results until unblinded. The enrollment rate for Phase 2 is exceeding expectations, and they target patients with mild cognitive impairment for the study.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.